Clene Inc.NASDAQ:CLNNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.3351
- TODAY'S CHANGE (%)0.0021 (0.6306%)
- Bid / Lots0.3252/ 50
- Ask / Lots0.3440/ 1
- Open / Previous Close0.3374 / 0.3330
- Day Range
- 52 Week Range
- Volume308,950
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CLNN |
|---|---|---|
| 09:32 ET | 5634 | 0.3399 |
| 09:34 ET | 100 | 0.3399 |
| 09:36 ET | 281 | 0.3373 |
| 09:39 ET | 110 | 0.3345 |
| 09:41 ET | 8540 | 0.3398 |
| 09:43 ET | 360 | 0.3398 |
| 09:45 ET | 1700 | 0.335 |
| 09:48 ET | 300 | 0.3352 |
| 09:52 ET | 100 | 0.3331 |
| 09:59 ET | 3183 | 0.331 |
| 10:03 ET | 894 | 0.331 |
| 10:06 ET | 1000 | 0.331 |
| 10:08 ET | 7990 | 0.33 |
| 10:10 ET | 10499 | 0.3326 |
| 10:15 ET | 492 | 0.3351 |
| 10:19 ET | 36021 | 0.3263 |
| 10:30 ET | 300 | 0.3279 |
| 10:32 ET | 100 | 0.329 |
| 10:33 ET | 1300 | 0.33165 |
| 10:35 ET | 2100 | 0.328 |
| 10:39 ET | 6100 | 0.3289 |
| 10:42 ET | 2371 | 0.332 |
| 10:46 ET | 280 | 0.332 |
| 10:50 ET | 6500 | 0.3281 |
| 11:00 ET | 300 | 0.3281 |
| 11:02 ET | 10301 | 0.3281 |
| 11:06 ET | 319 | 0.3281 |
| 11:08 ET | 152 | 0.3281 |
| 11:09 ET | 3000 | 0.3353 |
| 11:15 ET | 300 | 0.335299 |
| 11:18 ET | 130 | 0.3318 |
| 11:22 ET | 37572 | 0.3326 |
| 11:24 ET | 3500 | 0.337549 |
| 11:29 ET | 1000 | 0.335899 |
| 11:33 ET | 1479 | 0.3359 |
| 11:38 ET | 2945 | 0.34 |
| 11:40 ET | 200 | 0.3318 |
| 11:45 ET | 600 | 0.3318 |
| 11:58 ET | 374 | 0.34 |
| 12:02 ET | 100 | 0.33595 |
| 12:03 ET | 190 | 0.33595 |
| 12:05 ET | 1200 | 0.336 |
| 12:12 ET | 300 | 0.3319 |
| 12:14 ET | 100 | 0.335901 |
| 12:21 ET | 131 | 0.33595 |
| 12:25 ET | 250 | 0.3319 |
| 12:30 ET | 200 | 0.3319 |
| 12:48 ET | 1450 | 0.3319 |
| 01:24 ET | 500 | 0.3351 |
| 01:26 ET | 4319 | 0.3351 |
| 01:28 ET | 100 | 0.3351 |
| 01:33 ET | 1700 | 0.335174 |
| 01:39 ET | 500 | 0.3353 |
| 01:53 ET | 845 | 0.3352 |
| 01:57 ET | 12415 | 0.3352 |
| 02:04 ET | 2500 | 0.3376 |
| 02:06 ET | 26520 | 0.3352 |
| 02:08 ET | 7228 | 0.3353 |
| 02:15 ET | 700 | 0.3413 |
| 02:24 ET | 1000 | 0.3413 |
| 02:29 ET | 635 | 0.3387 |
| 02:33 ET | 100 | 0.3352 |
| 02:38 ET | 1000 | 0.3455 |
| 02:47 ET | 400 | 0.3351 |
| 02:51 ET | 100 | 0.341094 |
| 02:58 ET | 500 | 0.3401 |
| 03:02 ET | 4995 | 0.3401 |
| 03:03 ET | 10160 | 0.34 |
| 03:21 ET | 3000 | 0.3455 |
| 03:32 ET | 100 | 0.34275 |
| 03:39 ET | 100 | 0.34 |
| 03:41 ET | 10530 | 0.3421 |
| 03:52 ET | 1636 | 0.3419 |
| 03:54 ET | 1047 | 0.3445 |
| 03:56 ET | 146 | 0.34 |
| 03:57 ET | 2340 | 0.3447 |
| 03:59 ET | 1701 | 0.3351 |
Apr 17, 2024
DJ Clene Price Target Maintained With a $7.00/Share by HC Wainwright & Co., from 6:53AM ET on Wednesday Apr 17, 2024 by Dow Jones
6:53AM ET on Wednesday Apr 17, 2024 by Dow Jones
Apr 16, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Clene Inc. | 42.8M | -0.6x | --- |
Unicycive Therapeutics Inc | 40.0M | -0.7x | --- |
Apollomics Inc | 42.5M | -9.5x | --- |
IN8BIO, Inc. | 43.3M | -1.0x | --- |
SensaSure Technologies Inc | 42.3M | -21.8x | --- |
Matinas BioPharma Holdings Inc | 45.1M | -1.7x | --- |
Company Information
Clene Inc. is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis. It specializes in the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its CNM-Au8 is an investigational first-in-class therapy that improves central nervous system cells' survival and function via a mechanism that targets mitochondrial function and the nicotinamide adenine dinucleotide pathway while reducing oxidative stress. Its CNM-ZnAg is a broad-spectrum antiviral, antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions under development to treat infectious disease and to provide immune support for symptom resolution. Its CNM-AgZn17 is a gel polymer suspension of Zn2+ and Ag+ under development for treatment of infectious diseases and to support wound healing.
Contact Information
- Headquarters
- 6550 South Millrock Drive, Suite G50SALT LAKE CITY, UT, United States 84121
- Phone
- 801-676-9695
- Fax
- 302-531-3150
Executives
- Independent Chairman of the Board
- David Matlin
- President, Chief Executive Officer, Director
- Robert Etherington
- Co-Founder, Chief Science Officer
- Mark Mortenson
- Chief Financial Officer
- Morgan Brown
- Director, Co-Founder
- Reed Wilcox
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $42.8M |
|---|---|
Revenue (TTM) | $654.0K |
Shares Outstanding | 128.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.54 |
EPS | $-0.54 |
Book Value | $0.10 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | 65.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -6,198.78% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
